Head-To-Head Comparison: Biotricity (NASDAQ:BTCY) versus BrainsWay (NASDAQ:BWAY)
by Sarita Garza · The Markets DailyBiotricity (NASDAQ:BTCY – Get Free Report) and BrainsWay (NASDAQ:BWAY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.
Profitability
This table compares Biotricity and BrainsWay’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biotricity | -117.42% | N/A | -242.92% |
| BrainsWay | 1.67% | 1.45% | 0.96% |
Risk and Volatility
Biotricity has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Valuation and Earnings
This table compares Biotricity and BrainsWay”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biotricity | $12.06 million | 0.81 | -$14.09 million | ($1.32) | -0.34 |
| BrainsWay | $36.43 million | 4.41 | -$4.20 million | ($0.09) | -107.22 |
BrainsWay has higher revenue and earnings than Biotricity. BrainsWay is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
3.9% of Biotricity shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 10.0% of Biotricity shares are owned by company insiders. Comparatively, 19.0% of BrainsWay shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and price targets for Biotricity and BrainsWay, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biotricity | 0 | 1 | 0 | 0 | 2.00 |
| BrainsWay | 0 | 1 | 3 | 0 | 2.75 |
BrainsWay has a consensus price target of $13.17, indicating a potential upside of 36.44%. Given BrainsWay’s stronger consensus rating and higher probable upside, analysts plainly believe BrainsWay is more favorable than Biotricity.
Summary
BrainsWay beats Biotricity on 12 of the 14 factors compared between the two stocks.
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.